AbbVie (ABBV)
Health Care · Biopharmaceuticals · NYSE
A diversified global biopharmaceutical leader with a strong footprint in immunology, neuroscience, and aesthetics, supported by a pipeline expanding into obesity.
What AbbVie does
AbbVie is a global research-based biopharmaceutical company focused on developing and commercializing advanced therapies across the therapeutic areas of immunology, neuroscience, oncology, and aesthetics. The company's portfolio includes flagship products such as Skyrizi, Rinvoq, Humira, Vraylar, and Botox. AbbVie operates as a single global business segment, supported by a broad pipeline of compounds in various stages of clinical development.
Recent developments
In early 2026, AbbVie entered a voluntary agreement with the U.S. government to expand affordable patient access in exchange for a three-year exemption from tariffs and future price mandates. The company also announced significant U.S. capital investments, including a new pharmaceutical manufacturing campus in North Carolina and additional facilities in Illinois to support neuroscience and obesity programs.
From AbbVie's filing of 2026-10-05.
Themes: immunology, neuroscience, oncology, aesthetics, obesity supply chain, AI-driven manufacturing
Fundamentals
- Price$272.42 as of 2026-10-08 close
- Market cap$481.4B as of 2026-07-27 (share count; price 2026-10-08)
- 1-year return+17.8% 2025-10-08 close $231.24 → 2026-10-08 close $272.42
- P/E76.54 as of 2026-10-08
- Net margin+6.9% FY2025, SEC XBRL
- Debt / equity49.22 as of 2026-09-03
- Revenue growth (YoY)+10.4% as of 2026-09-03
- Revenue CAGR (3y)+1.8% SEC XBRL
- Beta0.27 as of 2026-09-03
- Last reported earnings2026-10-05 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +2.6%; 9-year non-decreasing per-share dividend streak (SEC XBRL).
How ABBV compares in its sector
- price-to-earnings ratiotop 25% 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldtop 25% 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, ABBV's dividend exceeded at least one reported measure of what it earned or generated (earnings payout 276%, free-cash-flow payout 65%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payout276% dividends / net income
- Free-cash-flow payout65% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How AbbVie looks technically
AbbVie (ABBV) is trading 17.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 64 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is 0.9% below its all-time high. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 17.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +17.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $258.51 | $258.51 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $232.41 | $232.41 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 266.92. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 64 trading days ago — a "golden cross", a bullish long-term signal | 64 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 20.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30) | 67.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($257.87 to $274.94) — its "stochastic" reading is 85 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 85.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $274.94 | $274.94 |
|---|---|---|
| From the 52-week high | it is 0.9% below its 52-week high (its highest price of the past year) | -0.9% |
| Above the 52-week low | it is 42.6% above its 52-week low (its lowest price of the past year) | +42.6% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.9% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $274.94 (set on 2026-10-07) | $274.94 |
| Given back of the 52-week move | over the past year its closes ranged ($197.38 to $272.42), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $223.64 to $226.05. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 0.9% below its all-time high | -0.9% |
| Nearest price level | it is trading 1.6% above a support level at $267.93 — a price it turned at three times since 2026-07-29, most recently on 2026-09-23. Since 2024-10-08 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.6% |
| All-time low | its lowest closing price on record is $32.51 (set on 2012-12-17) | $32.51 |
| Above the all-time low | it is 738.0% above its all-time low | +738.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.78 between its high and its low — about 2.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.78 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $257.67 and $271.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $257.67 – $264.34 – $271.01 |
| Typical daily range (% of price) | its price moves about 2.1% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.1% |
| Stretch from the 200-day average | it is trading 6.9 daily ranges above its 200-day average price (17.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.99× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.1% since the prior reading | +0.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Gap filled | a 2.3% gap up opened on 2026-07-28 has been "filled" 49 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 49 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 5 sessions in a row, a +4.81% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 5 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 8.5 percentage points (the stock gained 9.5% while the market gained 1.0%) | +8.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.0 percentage points (the stock gained 7.8% while the market gained 3.8%) | +4.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 14.3 percentage points (the stock gained 31.8% while the market gained 17.5%) | +14.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 2.8 percentage points (the stock gained 17.8% while the market gained 15.0%) | +2.8% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.0% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.7% of the share price. | +6.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 18% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $231.60 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | +17.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-07-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $257.01 — a volume-weighted average of daily closes over 68 sessions, not a true tick-by-tick VWAP. | +6.0% |
Price levels it has turned at before
ABBV last closed at $272.42 on 2026-10-08. Since 2024-10-08 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $267.93 | Support | 1.6% below the last close | turned there three times · 2026-07-29 to 2026-09-23 |
| $262.24 | Support | 3.7% below the last close | turned there three times · 2026-07-02 to 2026-09-03 |
| $243.03 | Support | 10.8% below the last close | turned there three times · 2025-10-01 to 2026-08-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $266.92.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $264.05 and $266.92 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 2 trading days, since 2026-10-07.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze · Near the all-time high | Learn: moving average · golden cross · adx · rsi · macd · breakout · all time high · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.70 mean, 1=Strong Buy…5=Strong Sell) — 28 analysts
- Mean price target$278.86 range $200.00 – $328.00; median $285.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ABBV
- Consensus EPS estimate$3.84 next reporting period, as of 2026-10-05
- Estimate change, 30 days-$0.0005 (-0.0%) from $3.84, on 2026-09-04, 31-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Potential for government-mandated price controls, including the impact of the Inflation Reduction Act on key products like Botox.","Reliance on a concentrated product portfolio, with long-term success dependent on R&D innovation and pipeline development.","Exposure to intense competition from biosimilars and other innovative therapies."]
What changed in the latest 10-Q
AI-assisted comparison of ABBV's 10-Q filed 2026-08-03 against the prior one filed 2026-05-08.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-03) reports financial performance for the six months ended June 30, 2026, including worldwide net revenues of $32.0 billion, operating earnings of $10.4 billion, diluted earnings per share of $2.42 and cash flows from operations of $7.3 billion; older filing (2026-05-08) reports results for the three months ended March 31, 2026 with net revenues of $15.0 billion, operating earnings of $4.0 billion, diluted EPS of $0.39 and cash flows from operations of $3.8 billion.
- Newer filing (2026-08-03) reports worldwide net revenues increased 11% on a reported basis and 10% on a constant currency basis for the six months ended June 30, 2026; older filing (2026-05-08) reports a 12% reported and 10% constant currency increase for the three months ended March 31, 2026.
- Newer filing (2026-08-03) includes $3.4 billion of intangible asset amortization and $3.9 billion change in fair value of contingent consideration liabilities for the six months ended June 30, 2026; older filing (2026-05-08) includes $1.7 billion amortization and $2.4 billion contingent consideration fair value change for the three months ended March 31, 2026.
- Newer filing (2026-08-03) states a device manufacturing facility acquisition in Arizona closed in July 2026.
- Newer filing (2026-08-03) adds Skyrizi developments: European Commission approval in June 2026 for children six years and older with moderate-to-severe plaque psoriasis, and U.S. FDA approval in June 2026 for children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis.
- Newer filing (2026-08-03) reports Rinvoq U.S. FDA application submission in February 2026 for adult and adolescent patients with non-segmental vitiligo, but does not mention a concurrent EMA application.
- Newer filing (2026-08-03) includes a joint Venclexta with acalabrutinib FDA approval announcement in February 2026.
- Newer filing (2026-08-03) includes Epkinly Phase 3 topline results announced in January 2026.
- Newer filing (2026-08-03) page footer is '2026 Form 10-Q | 23'.
- Removed:
- Older filing (2026-05-08) reports a Rinvoq application submission to the EMA for non-segmental vitiligo, which is absent from newer filing (2026-08-03).
- Older filing (2026-05-08) reports a Rinvoq U.S. FDA application submission in April 2026 for severe alopecia areata (AA), which is absent from newer filing (2026-08-03) excerpt.
- Newer filing does not include a Venclexta announcement that appeared in the older excerpt (the older excerpt in the provided text contains a Venclexta heading but the Newer excerpt truncates before that section).
- Reworded:
- Newer filing (2026-08-03) describes AbbVie selling products outside the United States through 'largely centralized national payer systems'; older filing (2026-05-08) says 'largely centralized national payers systems'.
- Newer filing (2026-08-03) says the U.S. Department of Health and Human Services acted 'through Centers for Medicare and Medicaid Services'; older filing (2026-05-08) says 'through Centers for Medicare and Medicaid Service'.
- Newer filing (2026-08-03) states the device manufacturing facility acquisition in Arizona 'closed in July 2026'; older filing (2026-05-08) only refers to 'an agreement to acquire' without a closing date.
- Newer filing (2026-08-03) form page footer is '2026 Form 10-Q | 23'; older filing page footer is '2026 Form 10-Q | 22' and includes a later page footer '2026 Form 10-Q | 23' associated with the Oncology subsection.
- Notes:
- The newer filing excerpt appears truncated mid-sentence at the Epkinly bullet (ending 'the Phase 3 trial evaluating Ep'), so changes to later sections (e.g., Oncology, Venclexta) could not be fully assessed.
- Both texts are excerpts and may not represent the complete MD&A section of either filing.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($8M) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 1 sell ($8M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-14. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ABBV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 34 matched disclosures for ABBV from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ABBV as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 265,994,087
- Reported value $66,934,752,012
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ABBV's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ABBV had 19,494,556 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ABBV had 1.10% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.48 days to cover at the same settlement.
- Reported short interest (shares) 19,494,556
- Short interest (% of shares outstanding) 1.10%
- Prior settlement (shares) 19,514,024
- Reported change -0.1%
- Days to cover (reported) 4.48
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Eli Lilly (LLY)
- Johnson & Johnson (JNJ)
- Merck & Co. (MRK)
- Novartis (NVS)
- Pfizer (PFE)
- Bristol Myers Squibb (BMY)
- Gilead Sciences (GILD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ABBV vs…
AbbVie is found in…
ABBV ranks in…
ABBV shows up in…
Frequently asked questions
What does AbbVie (ABBV) do?
AbbVie is a global research-based biopharmaceutical company focused on developing and commercializing advanced therapies across the therapeutic areas of immunology, neuroscience, oncology, and aesthetics. The company's portfolio includes flagship products such as Skyrizi, Rinvoq, Humira, Vraylar, and Botox. AbbVie operates as a single global business segment, supported by a broad pipeline of compounds in various stages of clinical development.
What sector is AbbVie (ABBV) in?
AbbVie (ABBV) is classified in the Health Care sector. Its industry is Biopharmaceuticals. It trades on NYSE.
Does ABBV pay a dividend?
Yes — AbbVie (ABBV) pays a dividend, with an indicated yield of about 2.62% and 9-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-09-03). Informational only — not financial advice.
Who are AbbVie's (ABBV) competitors?
Notable peers of AbbVie (ABBV) include Amgen, Eli Lilly, Johnson & Johnson, Merck & Co. and Novartis. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in ABBV?
Yes — we hold 34 matched STOCK Act disclosures for ABBV from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is AbbVie (ABBV) overbought or oversold right now?
AbbVie (ABBV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 67, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ABBV come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.